Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has shared an announcement.
Jiangsu Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Suncadia Biopharmaceuticals, has received approval from China’s National Medical Products Administration to market Retlirafusp alfa Injection, a class 1 innovative therapeutic biological product. The prescription biologic, dosed at 300 mg per vial, is approved in combination with fluorouracil and platinum-based chemotherapy as a first-line treatment for PD-L1 positive (CPS ≥ 1) locally advanced unresectable, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma, reinforcing Hengrui’s innovation pipeline and strengthening its competitive position in high-value oncology indications.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company focused on innovative drug research, development and commercialization, with a strong presence in oncology and biologic therapies. Through subsidiaries such as Suzhou Suncadia Biopharmaceuticals, it develops advanced therapeutic biological products for domestic and international markets.
Average Trading Volume: 3,561,372
Technical Sentiment Signal: Hold
Current Market Cap: HK$465.3B
For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.